Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly making false and misleading statements regarding its drug candidate's performance during a Phase III trial [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from August 3, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Ultragenyx created falsely optimistic beliefs about its drug candidate's performance, failing to achieve statistically significant endpoints despite positive communications [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].